Global Coalition Aims To Outpace Epidemics With New Vaccines

A global coalition of governments, health specialists and philanthropists will launch a new plan on Thursday to “outsmart” future disease epidemics with a fund to prepare and create new vaccines. Stung by the devastation of West Africa’s 2014-2015 Ebola outbreak, which killed more than 11,300 people before an effective vaccine was developed, the coalition is aiming to ensure such deadly outbreaks can’t happen again. John-Arne Rottingen, interim chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI), said it is designed as “a global insurance policy against epidemic and pandemic threats.” CEPI’s founders used the World Economic Forum in Davos to announce its launch, with initial funding of $460 million from the governments of Germany, Japan and Norway, the Bill &Melinda Gates Foundation and the Wellcome Trust global health charity. Bill Gates, co-chair of the Gates Foundation and a leading global health philanthropist, said recent major viral disease epidemics - Ebola and Zika - showed how the world “is tragically unprepared to detect local outbreaks and respond quickly enough to prevent them from becoming global pandemics”. “Without investments in research and development, we will remain unequipped when we face the next threat,” he said. “The ability to rapidly develop and deliver vaccines when new unknown diseases emerge offers our best hope to outpace outbreaks, save l...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 18 November 2019Source: Antiviral ResearchAuthor(s): Wanyu Dong, Wenting Xie, Yunbo Liu, Baokun Sui, Hao Zhang, Liran Liu, Yubei Tan, Xiaohan Tong, Zhen F. Fu, Ping Yin, Liurong Fang, Guiqing PengAbstractEmerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available. Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays. Moreover, A9 exhibited potent ...
Source: Antiviral Therapy - Category: Virology Source Type: research
Microbial Drug Resistance, Ahead of Print.
Source: Microbial Drug Resistance - Category: Microbiology Authors: Source Type: research
Applied Physiology, Nutrition, and Metabolism, e-First Articles. Gestational fructose exposure has detrimental health consequences on both the maternal and fetus or offspring in the early or later life, contributing to epidemic rise in cardiometabolic syndrome including cardiac events. l-Glutamine has been shown to mitigate cardiac metabolic stress. However, the effect of l-glutamine on cardiac hypertrophy induced by gestational fructose exposure is not known. We therefore hypothesized that l-glutamine would prevent gestational fructose-induced cardiac hypertrophy, possibly by suppression of pyruvate dehydrogenase kinase-4...
Source: Applied Physiology, Nutrition, and Metabolism - Category: Physiology Authors: Source Type: research
Publication date: Available online 18 November 2019Source: Fish &Shellfish ImmunologyAuthor(s): Defeng Zhang, Yanxia Gao, Qingyong Li, Xiaoli Ke, Zhigang Liu, Maixin Lu, Cunbin ShiAbstractStreptococcus agalactiae is an important pathogen associated with various aquatic animals, especially tilapia. Streptococcosis has greatly limited the healthy development of tilapia aquaculture in recent times. The development of novel effective vaccines is important for the prevention and control of streptococcosis in fish. We previously constructed a non-encapsulated S. agalactiae strain △cps by the in-frame deletion method. Here,...
Source: Fish and Shellfish Immunology - Category: Biology Source Type: research
In this study, an NDV isolate APMV-1/Chicken/China (SC)/PT3/2016 (hereafter referred as PT3) was identified as a class Ⅰ NDV and a lentogenic strain. The antigenic relationship between PT3 and 3 other NDV strains, including vaccine strain LaSota and 2 prevalent genotype Ⅶd and Ⅵb strains were analyzed. The protective efficacy of PT3 and LaSota against challenge with genotype Ⅶd and Ⅵb strains were assessed. The antigenic analysis result showed that 4 strains belong to the single serotype and the PT3 antiserum exhibited the highest HI titer against 3 other NDV strains. The results of protective efficacy showed tha...
Source: Biologicals - Category: Biology Source Type: research
Publication date: November 2019Source: Chinese Journal of Analytical Chemistry, Volume 47, Issue 11Author(s): Can-Can ZHU, Jun-Sheng CUI, An-Zhong HU, Ke YANG, Jun ZHAO, Yong LIU, Guo-Qing DENG, Ling ZHUAbstractInfectious diseases caused by highly pathogenic microorganisms are the main factors threatening human health and causing social panic. To simultaneously detect bacteria and viruses in a single test, a PCR-Array chip based on solid phase PCR (SP-PCR) was developed, in which an ultraviolet cross-linking method was used to fix oligonucleotide sequence on the grass to develop a PCR array chip for detection of Crimea-Con...
Source: Chinese Journal of Analytical Chemistry - Category: Chemistry Source Type: research
In Middleton, Wisconsin, an NSF-supported small business is expanding on ways to make everything from biopesticides to vaccines – all on the surface of leaves! How does this innovative approach to chemical manufacturing help us use the greenest, most renewable chemical factories on earth? Ryan and ...This is an NSF Multimedia Gallery item.
Source: NSF Multimedia Gallery - Category: Science Source Type: video
Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43]. Eur J Pharm Biopharm. 2019 Dec;145:96-97 Authors: Tan Z, Liu W, Liu H, Li C, Zhang Y, Meng X, Tang T, Xi T, Xing Y PMID: 31735275 [PubMed - in process]
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Biopharm Source Type: research
Condition:   Pneumonia, Pneumococcal Interventions:   Drug: pPCV;   Biological: Pneumovax™23 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Human Papillomavirus Infection Intervention:   Other: biological sample analysis Sponsor:   Centre Hospitalier Universitaire de Besancon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Ebola | Ebola Vaccine | Epidemics | Epidemiology | Funding | Insurance | International Medicine & Public Health | Lassa Fever | MERS | Middle East Health | Nipah Virus | Outbreaks | Pandemics | Partnerships | Respiratory Medicine | Vaccines | Websites | WHO | Zika Virus